Drugs / Superparamagnetic Iron Oxide
Superparamagnetic Iron Oxide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05359783 | Nov 2021 → Feb 2023 | breast cancer | Vastra Gotaland Region | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06169072 | Jan 2023 → Jul 2024 overdue | breast cancer | Vastra Gotaland Region | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Superparamagnetic Iron Oxide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05359783 ↗ |
| Modality | Diagnostic / imaging agent | “to evaluate if it is possible to map and stage sentinel lymph nodes with SPIO-enhanced axillary MRI.” NCT05359783 ↗ |